New drug trial aims to ease droopy eyelids and double vision
NCT ID NCT07463521
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an investigational drug called rozanolixizumab against a placebo in 120 adults with ocular myasthenia gravis, a condition causing eye muscle weakness like droopy eyelids or double vision. Participants receive the drug or placebo by injection, and researchers measure changes in eye symptoms after about 6 weeks. The goal is to see if the drug safely reduces symptom severity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mg0038 10103
RECRUITINGColumbus, Ohio, 43210, United States
-
Mg0038 10106
RECRUITINGAmherst, New York, 14226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.